INIvana Novakovic

Ivana Novakovic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ivana Novakovic has a total of 257 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ACE gene and male infertility: a South Slavic case-control study and multi-omics data integration

    by Tanja Kunej, Rebeka Podgrajsek, Helena Jaklic, Alenka Hodzic, Martin Stimpfel, Olivera Miljanovic, Momcilo Ristanovic, Ivana Novakovic, Dijana Plaseska-Karanfilska, Predrag Noveski, et al.

    Components of the renin-angiotensin system (RAS) are expressed in both female and male reproductive tracts, with angiotensin I converting enzyme (ACE) being an important component for male reproductive function, as shown in animal models. The most studied ACE polymorphism is the Alu insertion-deletion (I/D), which has been proposed to have a negative effect on male fertility. Given the conflicting evidence in the literature, we conducted a multicentric case-control study to investigate the association between the ACE Alu I/D polymorphism and impaired spermatogenesis. Using PCR amplification and agarose electrophoresis, we genotyped the ACE gene Alu I/D polymorphism in 745 South Slavic men. The study group consisted of 457 patients with impaired spermatogenesis, 239 with non-obstructive azoospermia (NOA) and 218 with oligoasthenoteratozoospermia (OAT) and a control group of 288 fertile men. No association was found between the Alu I/D polymorphism and these semen phenotypes, suggesting that it is not associated with NOA or severe OAT in this cohort. To provide a broader regulatory context, we also developed an integrative atlas of ACE regulatory elements by in silico multi-omics analysis using genomics databases and bioinformatics tools. Data integration revealed various regulatory mechanisms at multiple omics levels, including genomics, epigenomics, miRNAomics, transcriptomics, proteomics and epiproteomics. These include genomic variants with predicted deleterious effects, a CpG island, microRNAs (miRNAs) and post-translational modifications (PTMs). In addition, protein interaction analysis revealed that ACE is indirectly linked to several proteins previously associated with male infertility and is also targeted by miRNA previously associated with oligozoospermia. This comprehensive, multi-faceted approach, combining genetic association analysis with bioinformatics, provides insights into ACE regulation in its broader molecular context. These results emphasize the importance of further integrative multi-omics and systems biology research to better understand the role of ACE in male reproductive function.

  • Is GBA1 mutation status a game-changer for impulse control behaviour in Parkinson's disease?

    by Nikola Kresojević, Vladana Marković, Cveta Geratović, Milica Ječmenica Lukić, Aleksandra Tomić, Valerija Dobričić, Iva Stanković, Tanja Stojković, Nataša Dragašević, Maksim Šarčević, et al.

    Objective The GBA1 related Parkinson’s disease (PD) is associated with more severe non-motor symptoms. To date, studies of the role of GBA1 mutations in the occurrence of impulse control behaviours (ICBs) in PD have yielded controversial results. Our aim was to investigate the frequency and characteristics of ICBs in PD patients with GBA1 mutations. Methods 213 consecutive PD patients were included. Clinical data were gathered via interviews and using the standard set of questionnaires. Genetic analysis of exons 8–11 of the GBA1 gene was performed for all participants. Results GBA1 variants were detected in 32 out of 213 patients (GBA-PD). ICBs were more frequent in GBA-PD (31.2%) than in non-mutated PD (nmPD) group (25.9%), though not significantly. Among patients with ICBs and GBA1 variants female sex predominance was observed (60%, p = 0.022). GBA-PD patients with ICBs had a significantly shorter disease and therapy duration, lower total LEDD and QUIP when comparing to nmPD with ICBs. Binary logistic regression showed that age, BDI score, LEDD, and male sex significantly predicted ICBs in the whole sample. In the GBA-PD group, only dopamine agonist use, and a lower UPDRS Part I score were significant predictors. Conclusion Dopaminergic treatment is a significant risk factor for ICBs, irrespective of GBA1 mutation status. GBA1 mutations may increase susceptibility to dopaminergic dose-related ICBs adverse effects, particularly in PD patients with fewer non-motor symptoms, and may affect the sex distribution in PD patients with ICBs, potentially attenuating the male predominance.


  • Open Access

    Significance of molecular biomarkers in the diagnosis of neuromyelitis optica spectrum disorder

    by Marko Andabaka, Jelena Drulović, Ivana Novaković

    Discovery of antibodies to aquaporin-4 channels as a laboratory or molecular biomarker for neuromyelitis optica spectrum disorder contributed to a better understanding of the etiopathogenesis, with a clear separation of the clinical, neuroradiological and laboratory characteristics of this disease. This resulted in the definition of criteria for establishing the diagnosis of neuromyelitis optica spectrum disorder and a clear distinction in relation to multiple sclerosis. Clinical presentation of the inflammatory diseases of the central nervous system may be highly variable, with numerous, often overlapping symptoms and signs. Therefore, in the differential diagnostic, in addition to the clinical presentation, it is necessary to consider paraclinical characteristics, such as laboratory findings of the blood and cerebrospinal fluid and the neuroradiological examination findings. Since aquaporin-4 is a clearly defined, crucial diagnostic biomarker in the neuromyelitis optica spectrum disorder, different methodological approaches were developed to evaluate antibodies to aquaporin-4, taking into account the specificity and sensitivity of the tests themselves. One of the first tests that was routinely applied in clinical practice for the detection of antibodies to aquaporin-4, were tests in the form of an immunoenzymatic assay that showed great variability in the degree of specificity and sensitivity. The second group of tests for the detection of antibodies to aquaporin-4 applied the technique of indirect immunofluorescence on a substrate of animal origin, which achieved a higher degree of sensitivity and specificity, with certain disadvantages, such as the impossibility of precise quantification as well as difficulties in the interpretation of the results. Special methodological principles of immunoprecipitation such as fluorescent and radioimmunoprecipitation did not achieve a satisfactory level of sensitivity in the detection of antibodies to aquaporin-4. The highest level of sensitivity with absolute specificity has been achieved via developing a cell assay methodology, based on the application of human aquaporin-4 transfected cells fixed on a biochip, with a negative control when antibodies to aquaporin-4 from serum are detected by indirect immunofluorescence methodology or special cellular assays, and when these antibodies are quantified by flow cytometry method. Using this cell assay methodology is extremely important in order to establish the correct diagnosis of seropositive neuromyelitis optica spectrum disorder.

  • Open Access

    Significance of interactions between genetic and environmental factors in etiology of multiple sclerosis

    by Aleksa Jovanović, Tatjana Pekmezović, Šarlota Mesaroš, Ivana Novaković

    Multiple sclerosis (MS) is an immune-mediated disorder of central nervous system. It most frequently occurs in young female adults, and the prevalence increases with latitude. So far, over 200 genes, loci and single nucleotide polymorphisms (SNPs) have been linked with MS, although each one contributing only slightly in the overall etiology of the disease. The HLA-DRB1*15:01 haplotype has been shown to have the strongest association with MS occurrence risk in genome-wide association studies (GWAS), while HLA-A*02 has been shown to have a protective effect. The exact etiology of MS is still unclear, but there seems to exist an interplay between genetic burden of an individual, and environmental factors which contribute to MS occurrence such as Epstein-Barr virus (EBV) infection, vitamin D levels, smoking status, and early life obesity. An interaction between HLA-DRB1*15:01 and EBV infection, the strongest environmental risk factor for MS, has been observed. It has been suggested that this interaction is a result of HLA-DRB1*15:01 acting as a coreceptor for EBV, thus providing a pathophysiological explanation connecting environmental with genetic MS risk factors. A recent study including participants from two case-control studies with over 13.000 individuals showed that an interaction exists between sun exposure, vitamin D levels, and HLA-DRB*15:01 carrier status, leading to increased risk of MS in individuals with lower sun exposure, vitamin D deficient, and HLA-DRB*15:01 positive. The interaction of HLA-DRB1*15:01 with smoking has been observed in a meta-analysis, while the same study only showed an interaction of smoking with the absence of HLA-A*02 in a subset of studies. The risk of MS has been shown to vary in obese individuals, with obese individuals with the susceptible genotype (HLA-DRB1*15:01+, HLA-A*02-) having 16x higher odds of having MS compared with non-obese persons with a non-susceptible genotype.


  • Open Access

    Genetic Testing for Monogenic Forms of Male Infertility Contributes to the Clinical Diagnosis of Men with Severe Idiopathic Male Infertility

    by Rebeka Podgrajsek, Alenka Hodzic, Ales Maver, Martin Stimpfel, Aleksander Andjelic, Olivera Miljanovic, Momcilo Ristanovic, Ivana Novakovic, Dijana Plaseska-Karanfilska, Predrag Noveski, et al.

    Podgrajsek R, et al. World J Mens Health. 2025 Jan;43:e1. https://doi.org/10.5534/wjmh.240149


  • Open Access

    Influence of TMPRSS6 genotype on iron status parameters in stable COPD patients

    by Marko Trtica, Ivana Novaković, Violeta Dopsaj, Branislava Milenković, Jelena Janković, Sanja Dimić-Janjić, Vesna Dopuđa-Pantić, Jelena Martinović, Snežana Jovičić

    Background: The SNP rs855791 has been linked to increased hepcidin levels, variations in serum iron, transferrin saturation and red blood cell indices. Our goal was to determine the prevalence of this polymorphism among COPD patients and to assess its impact on iron status parameters in patients with stable COPD. Methods: We analysed iron status parameters and genetic data from 29 COPD patients with wild-type genotype (WT group) and 65 COPD patients with either homozygous or heterozygous genotype (HH group). Additionally, the prevalence of SNP rs855791 was assessed in 192 volunteers. Results: The frequency distribution of SNP rs855791 was comparable between the COPD patients and control subjects (p=0.791). Iron status parameters were within their respective reference values and showed neither statistically nor clinically significant difference between the WT and HH group of COPD patients. However, after excluding patients with (sub)clinical vitamin B12 deficiency and/or hypoxemia, WT group of patients exhibited significantly lower erythropoietin levels (p=0.015). The area under the curve for erythropoietin was 0.688 (95% CI: 0.545-0.830, p=0.015), with an optimal cut-off of 9.74, sensitivity of 61.2% (95% CI: 58.1-64.3) and specificity of 65.0% (95% CI: 61.8-68.3).Conclusions: Iron status parameters do not differ between WT and HH groups of stable COPD patients. Statistical but not clinical difference in EPO levels was observed in a subgroup of patients. In addition to promoting erythropoiesis, EPO may regulate hepcidin levels and thus influence the development of iron deficiency and/or anaemia. Also, EPO's direct effect on immune cells and down-regulation of inflammatory reactions should be considered in this context.

  • Open Access

    Management of Pregnancy in a Patient with Familial Hypercholesterolemia and Previous Myocardial Infarction—Treatment with LDL Apheresis: A Case Report

    by Milos Milincic, Jovana Todorovic, Stefan Dugalic, Ivana Novakovic, Maja Macura, Katarina Lalic, Miroslava Gojnic Dugalic

    Familial hypercholesterolemia, a genetic disorder marked by elevated low-density lipoprotein cholesterol (LDL-C), poses significant risks for premature atherosclerosis and cardiovascular diseases, particularly during pregnancy. One of the safe methods of treating this condition in pregnancy is with the use of LDL apheresis. We present a 38-year-old primigravida with homozygous Familial Hypercholesterolemia (HoFH), ischemic cardiomyopathy, and angina pectoris. Two years before conception, extremely elevated lipid levels prompted statin therapy and lifestyle changes. Stent placements followed acute myocardial infarction. When planning pregnancy, statins were discontinued, but lipid levels elevated. LDL apheresis was initiated, achieving a 60% reduction. Throughout pregnancy, 16 LDL apheresis sessions were performed every 14 days, maintaining optimal lipid profiles. A cesarean section was performed in the 38th week of gestation, delivering a healthy infant. The patient resumed statin therapy after 8 months of breastfeeding. The patient maintained cardiovascular health, demonstrating the feasibility of controlled HoFH pregnancies. This case highlights the successful management of HoFH during pregnancy using LDL apheresis, ensuring maternal and fetal well-being. Future research on novel treatments and their safety during pregnancy is essential for refining therapeutic approaches in similar cases.

  • Open Access

    Genetic and epigenetic mechanisms of aging

    by Ivana Novaković, Tamara Filipović, Nela Maksimović, Dejan Nikolić

    Aging is inevitable and the representation of old people in the population grows. Accordingly, the understanding of genetic factors and physiological mechanisms involved in the process of normal aging is of increasing importance for maintaining the quality of life in old age. Preserving the physiological functions or "health" of old people will reduce pressure on health systems and costs. In this review, in the light of the latest scientific data and hypotheses, some key questions regarding the genetics, biology and physiology of aging are briefly discussed: what is aging, why it occurs and what are the possibilities of delaying and slowing down of aging.

  • Open Access

    GATOR1 gene variants in focal epilepsy

    by Maša Kovačević, Nikola Vojvodić, Ivana Novaković

    Significant genetic contributions to focal epilepsy have only recently been recognized, despite the well-established hereditary nature of other epilepsy syndromes. In 2013, the significant role of the DEPDC5 gene in a rare familial focal epilepsy syndrome was described, followed by the discovery of variants in NPRL2 and NPRL3 genes in patients with similar clinical features three years later. The genes listed above code the three subunits that comprise the GTPase-activating protein (GAP) activity towards Rags 1 (GATOR1) complex, a negative regulator of the mechanistic target of rapamycin (mTOR) complex 1 (mTORC1). Loss of function of GATOR1 leads to constitutive mTORC1 activation that is linked to various malformations of cortical development (MCD), most notoriously focal cortical dysplasia (FCD), but has also been linked to epilepsy in the absence of overt MCD. Variants in GATOR1 genes have been detected in multiplex families with rare familial focal epilepsy syndromes where they demonstrate an autosomal dominant inheritance pattern with reduced penetrance. More recently, they have also been defined as major contributors in common nonacquired focal epilepsy in which they are detected in 3% of familial and 0.2% of sporadic cases and are particularly common in familial epilepsy associated with FCD where up to 11% of affected subjects carry gene variants. Clinical features of carriers include a propensity for nocturnal seizures, a poor response to antiseizure medication as well and an increased risk of sudden unexpected death in epilepsy, which is why other forms of treatment have been explored, including epilepsy surgery after which GATOR1 gene variant carriers have similar outcomes to other patients with focal epilepsy. A particularly promising avenue of exploration is the utilization of mTOR inhibitors like everolimus in epilepsy treatment, but further investigation into this option is warranted.


  • Open Access

    Challenges in rare diseases: The example of mitochondrial diseases

    by Ivana Novaković, Milena Janković, Ana Marjanović, Marija Branković, Marina Svetel, Jasna Jančić

    Background: Mitochondrial diseases are a group of disorders caused by dysfunction of mitochondria - the organelles that generate energy for the cell by converting the energy of food molecules into the ATP that powers most cell functions. Mitochondrial diseases are one of the most common groups of rare diseases with a minimum prevalence of greater than 1 in 5000 in adults. Clinical manifestations of mitochondrial diseases are heterogonous, mostly affecting nervous and muscle systems and sensory organs; symptoms can appear at birth or they may not appear until adulthood These diseases have genetic basis, and could be caused by mutations in nuclear genes, as well as by mutations in mitochondrial DNA (mtDNA) - small, maternally inherited, DNA molecule. An additional aspect of their genetic complexity is given by phenomenon of mtDNA heteroplasmy. Having all this in mind, the detection of the causative gene mutation is of crucial importance for diagnostics and further management of mitochondrial diseases. In addition, development of new therapeutic strategies is based on best knowledge ate genomic level. Methods and objectives: Genetic analyses were performed at patients suspect with mitochondrial diseases in order to detect causative gene mutations. Applied methods were targeted sequencing of mtDNA and clinical exome analysis by next generation sequencing. Results: In this report we will present our experience with genetic testing of mitochondrial diseases, challenges in genetic counselling, and possible new therapeutic options in mitochondrial diseases. Conclusion: Modern management of mitochondrial diseases is based on their genetic diagnostics. Contemporary algorithms and guidelines should be applied in this field of rare diseases.